NASDAQ:PROC - Nasdaq - LU2376511205 - Common Stock - Currency: USD
1.01
-0.58 (-36.51%)
The current stock price of PROC is 1.01 USD. In the past month the price decreased by -56.65%. In the past year, price decreased by -68.92%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 71.52 | 882.60B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.7 | 403.33B | ||
JNJ | JOHNSON & JOHNSON | 16.53 | 397.55B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 21.54 | 241.77B | ||
MRK | MERCK & CO. INC. | 12.2 | 235.74B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.09 | 220.97B | ||
SNY | SANOFI-ADR | 14.43 | 148.30B | ||
PFE | PFIZER INC | 8.34 | 147.00B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 52.47 | 121.33B | ||
GSK | GSK PLC-SPON ADR | 8.14 | 79.20B | ||
ZTS | ZOETIS INC | 28.21 | 75.35B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 34.18 | 47.68B |
Procaps Group SA is an international healthcare and pharmaceutical company. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.
PROCAPS GROUP SA
9, rue de Bitbourg
Luxembourg LU
CEO: Kyle P. Bransfield
Employees: 5500
Company Website: https://www.procapsgroup.com/
Investor Relations: https://investor.procapsgroup.com/
The current stock price of PROC is 1.01 USD. The price decreased by -36.51% in the last trading session.
The exchange symbol of PROCAPS GROUP SA is PROC and it is listed on the Nasdaq exchange.
PROC stock is listed on the Nasdaq exchange.
6 analysts have analysed PROC and the average price target is 5.1 USD. This implies a price increase of 404.95% is expected in the next year compared to the current price of 1.01. Check the PROCAPS GROUP SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PROCAPS GROUP SA (PROC) has a market capitalization of 113.95M USD. This makes PROC a Micro Cap stock.
PROCAPS GROUP SA (PROC) currently has 5500 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PROC does not pay a dividend.
ChartMill assigns a technical rating of 1 / 10 to PROC. When comparing the yearly performance of all stocks, PROC is a bad performer in the overall market: 96.48% of all stocks are doing better.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 43% to PROC. The Buy consensus is the average rating of analysts ratings from 6 analysts.